


Dapagliflozin: Reductions in HbA_{1c} at 52 weeks were sustained over 104 weeks^{1,2}



Short-term plus long-term treatment period full analysis set. Non-inferiority was met at 52 weeks. P-value was not available at 104 weeks. Data are adjusted mean change from baseline and 95% confidence interval (CI) derived from a repeated measures mixed model.

*Dapagliflozin dose was up-titrated to a maximum of 10mg (achieved in 87% of patients) over an 18-week period based on glycaemic response and tolerability.

1. Nauck MA *et al*. *Diabetes Care* 2011;**34**:2015–2022.

2. Nauck M *et al*. Poster 40-LB. Poster presented at 71st Scientific Sessions of the American Diabetes Association, San Diego, California, 24–28 June, 2011.